DexCom Inc (DXCM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DexCom Inc (DXCM) has a cash flow conversion efficiency ratio of 0.107x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($294.00 Million) by net assets ($2.75 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DexCom Inc - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how DexCom Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read DXCM liabilities breakdown for a breakdown of total debt and financial obligations.
DexCom Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DexCom Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hanmi Semicon
KO:042700
|
0.128x |
|
POSCO Holdings
KO:005490
|
0.004x |
|
HANSOH PHARMAC. HD-00001
F:3KY
|
N/A |
|
ABN AMRO BK.UNSP.ADR/1
F:AB2A
|
N/A |
|
Ulta Beauty Inc
NASDAQ:ULTA
|
0.002x |
|
Banco Do Brasil SA
F:BZLA
|
0.255x |
|
ABN Amro Group NV
AS:ABN
|
0.009x |
|
CMS Energy Corporation
NYSE:CMS
|
0.049x |
Annual Cash Flow Conversion Efficiency for DexCom Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of DexCom Inc from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see DXCM market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.75 Billion | $1.44 Billion | 0.525x | +11.48% |
| 2024-12-31 | $2.10 Billion | $989.50 Million | 0.471x | +30.06% |
| 2023-12-31 | $2.07 Billion | $748.50 Million | 0.362x | +15.22% |
| 2022-12-31 | $2.13 Billion | $669.50 Million | 0.314x | +44.93% |
| 2021-12-31 | $2.04 Billion | $442.50 Million | 0.217x | -16.78% |
| 2020-12-31 | $1.83 Billion | $475.60 Million | 0.260x | -26.93% |
| 2019-12-31 | $882.60 Million | $314.50 Million | 0.356x | +91.85% |
| 2018-12-31 | $663.30 Million | $123.20 Million | 0.186x | -15.33% |
| 2017-12-31 | $419.40 Million | $92.00 Million | 0.219x | +10.77% |
| 2016-12-31 | $283.80 Million | $56.20 Million | 0.198x | -10.61% |
| 2015-12-31 | $221.20 Million | $49.00 Million | 0.222x | +31.60% |
| 2014-12-31 | $140.20 Million | $23.60 Million | 0.168x | +489.86% |
| 2013-12-31 | $84.10 Million | $2.40 Million | 0.029x | +106.64% |
| 2012-12-31 | $77.00 Million | $-33.10 Million | -0.430x | -49.10% |
| 2011-12-31 | $104.49 Million | $-30.13 Million | -0.288x | +58.79% |
| 2010-12-31 | $60.99 Million | $-42.68 Million | -0.700x | -132.76% |
| 2009-12-31 | $-18.45 Million | $-39.39 Million | 2.135x | +120.17% |
| 2008-12-31 | $-38.61 Million | $-37.45 Million | 0.970x | +120.78% |
| 2007-12-31 | $7.12 Million | $-33.21 Million | -4.667x | -506.45% |
| 2006-12-31 | $56.83 Million | $-43.73 Million | -0.770x | -68.61% |
| 2005-12-31 | $49.41 Million | $-22.55 Million | -0.456x | -281.09% |
| 2004-12-31 | $-49.31 Million | $-12.43 Million | 0.252x | -13.15% |
| 2003-12-31 | $-32.60 Million | $-9.46 Million | 0.290x | -- |
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick bloo… Read more